Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Hip fracture is both a cause and a consequence of sarcopenia. Older persons with sarcopenia have an increased risk of falling, and the prevalence of sarcopenia may be increased in those who suffer a hip fracture. The aim of this study was to explore potential biomarkers (neuromuscular and peripheral pro‐inflammatory and oxidative stress markers) that may be associated with sarcopenia in very old persons with hip fracture.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We recruited 150 consecutive patients ≥80 years old admitted to an orthogeriatric unit for an osteoporotic hip fracture. Muscle mass was assessed pre‐operatively using bioelectrical impedance analysis; Janssen's (J) and Masanés' (M) reference cut‐off points were used to define low muscle mass. Muscle strength was assessed with handgrip strength (Jamar's dynamometer). Sarcopenia was defined by having both low muscle mass and strength and using the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia (low grip strength). Peripheral markers—pro‐inflammatory and oxidative stress parameters—were determined either in the plasma or in the erythrocyte fraction obtained from peripheral whole blood of every patient pre‐operatively.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Mean age was 87.6 ± 4.9 years, and 78.7% were women. The prevalence of sarcopenia was 11.5% with Janssen's, 34.9% with Masanés' cut‐offs, and 93.3% with the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia. Among the four pro‐inflammatory cytokines tested in plasma, only tumour necrosis factor‐α was different (lower) in sarcopenic than in non‐sarcopenic participants using both muscle mass cut‐offs (J 7.9 ± 6.2 vs. 8.3 ± 5.8, M 6.8 ± 4.7 vs. 9.1 ± 6.2). Erythrocyte glutathione system showed a non‐significant tendency to lower glutathione levels and glutathione/oxidized glutathione ratios in sarcopenic participants compared with non‐sarcopenic subjects. Catalase activity was also lower in sarcopenic participants (J 2904 ± 1429 vs. 3329 ± 1483, M 3037 ± 1430 vs. 3431 ± 1498). No significant differences were found between groups in chymotrypsin‐like activity of the 20S proteasome, superoxide dismutase, glutathione peroxidase and butyrylcholinesterase activity, C‐terminal agrin fragment, interferon‐γ, or interleukin‐1β.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The prevalence of sarcopenia in patients with hip fracture varies according to the definition and the muscle mass reference cut‐off points used. We did not find differences in most neuromuscular, pro‐inflammatory, or oxidative stress markers, except for lower peripheral tumour necrosis factor‐α levels and catalase activity in sarcopenic participants, which may be markers of an early inflammatory reaction that is hampered in sarcopenic patients.</p></section>

Plasma heat shock protein 72 as a biomarker of sarcopenia in elderly people

Serum GDF15 Level Is Independent of Sarcopenia in Older Asian Adults

Associations Between Elevated Growth Differentiation Factor-15 and Sarcopenia Among Community-dwelling Older Adults

Evaluation of Sarcopenia in Elderly Women of China

Sixteen weeks of resistance training decrease plasma heat shock protein 72 (eHSP72) and increase muscle mass without affecting high sensitivity inflammatory markers' levels in sarcopenic men

A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study

Plasma acylcarnitine in elderly Taiwanese: as biomarkers of possible sarcopenia and sarcopenia

Plasma biomarkers in patients with age-related sarcopenia: a proteomic exploration and experimental validation

Possible-sarcopenic screening with disturbed plasma amino acid profile in the elderly

Cross-sectional associations among P3NP, HtrA, Hsp70, Apelin and sarcopenia in Taiwanese population

Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men

From a solitary blood-derived biomarker to combined biomarkers of sarcopenia: Experiences from the Korean Frailty and Aging Cohort Study

High circulating adiponectin levels predict decreased muscle strength among older adults aged 70 years and over: A prospective cohort study.

Elevated level of the soluble receptor for advanced glycation end-products involved in sarcopenia: an observational study

Advanced glycation end products are associated with sarcopenia in older women: aging marker dynamics

Whole Blood Spermine/Spermidine Ratio as a New Indicator of Sarcopenia Status in Older Adults

Plasma C‐terminal agrin fragment concentrations across adulthood: Reference values and associations with skeletal muscle health

Predict Sarcopenia Risk in the Elderly by Cardiovascular Function and Heart Rate Variability

Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia

Biomarkers of sarcopenia in very old patients with hip fracture

Tracking the Plasma C-Terminal Agrin Fragment as a Biomarker of Neuromuscular Decline in 18- to 87-Year-Old Men